other material
confidence high
sentiment positive
materiality 0.85
SAB Biotherapeutics reports positive Phase 3 results for SAB-185 in high-risk COVID-19 patients
SAB Biotherapeutics, Inc.
- 66% of SAB-185 patients reached sustained symptom resolution by Day 28 vs 50% for REGEN-COV (p=0.010).
- Median time to symptom resolution was 7 days shorter for SAB-185 vs REGEN-COV (p=0.010).
- Primary endpoint (hospitalization/death) inconclusive due to low events after Omicron emergence.
- Grade 3+ adverse event rates similar between SAB-185 and REGEN-COV arms.
- SAB-176 for influenza granted Fast Track and Breakthrough Therapy designations from FDA.